INT22285

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1990
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 16
Total Number 17
Disease Relevance 7.84
Pain Relevance 8.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mtx1)
Anatomy Link Frequency
ADAL 2
liver 1
CSF 1
body 1
Mtx1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 816 100.00 Very High Very High Very High
Etanercept 253 100.00 Very High Very High Very High
Adalimumab 116 100.00 Very High Very High Very High
Infliximab 189 99.96 Very High Very High Very High
abatacept 57 99.80 Very High Very High Very High
cINOD 42 99.60 Very High Very High Very High
Pain 47 98.32 Very High Very High Very High
Inflammation 81 97.84 Very High Very High Very High
intrathecal 12 97.36 Very High Very High Very High
Central nervous system 11 95.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diarrhoea 5 99.98 Very High Very High Very High
Vomiting 15 99.72 Very High Very High Very High
Pressure And Volume Under Development 7 98.76 Very High Very High Very High
Disease 148 98.68 Very High Very High Very High
Cancer 23 98.52 Very High Very High Very High
INFLAMMATION 90 97.84 Very High Very High Very High
Hypersensitivity 9 95.12 Very High Very High Very High
Nociception 20 95.08 Very High Very High Very High
Malignant Neoplastic Disease 12 94.68 High High
Aneurism 5 93.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Based on these results, the investigators pointed out the necessity of considering MTX dose reduction when the NSAID dose is increased or additional NSAIDs are used.


Negative_regulation (reduction) of MTX associated with cinod and methotrexate
1) Confidence 0.49 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.33 Pain Relevance 1.25
Following a low oral dose of MTX (?
Negative_regulation (dose) of MTX associated with methotrexate
2) Confidence 0.36 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.26 Pain Relevance 0.35
However, if one particular subject that had a very low clearance when receiving MTX alone was excluded, there was a statistically significant decrease in MTX clearance when either ASA or SUL were present.
Negative_regulation (decrease) of MTX associated with methotrexate
3) Confidence 0.36 Published 1990 Journal J Pharm Sci Section Abstract Doc Link 2273459 Disease Relevance 0.21 Pain Relevance 0.97
On another hand CsA, Cy and Mtx were inactive on the 3-h phase but decreased the 24-h phase of carrageenin edema.
Negative_regulation (decreased) of Mtx associated with pressure and volume under development
4) Confidence 0.35 Published 1990 Journal Arzneimittelforschung Section Abstract Doc Link 2291750 Disease Relevance 1.26 Pain Relevance 0.43
Gastrointestinal: nausea, vomiting or diarrhoea precluding MTX continuation.Abnormal liver function: liver transaminases ?
Negative_regulation (precluding) of MTX in liver associated with diarrhoea, vomiting and methotrexate
5) Confidence 0.32 Published 2008 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2468887 Disease Relevance 0.67 Pain Relevance 0.43
Alternatively, upregulation of the efflux transporter ABCG2 protein expression has been associated with MTX resistance in cancer cells [45], but no associations with SNPs evaluated in FPGS and clinical effects of MTX have been observed [44].
Negative_regulation (effects) of MTX associated with cancer and methotrexate
6) Confidence 0.29 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.45 Pain Relevance 0.27
This study aims to analyze the interference of MTX and CsA, each one daily administered alone or combined during 21 days, on the activity levels of S DPPIV and POP, and MDPPIV in two distinct status of ex
Spec (analyze) Negative_regulation (interference) of MTX associated with methotrexate
7) Confidence 0.25 Published 2008 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2266974 Disease Relevance 1.00 Pain Relevance 0.66
Patients who received folic acid supplements had decreased 7-OH-MTX excretion (P=0.03).
Negative_regulation (decreased) of MTX
8) Confidence 0.23 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.06 Pain Relevance 0
The median value of maximum body temperatures decreased significantly within 24 hours of initiating MTX treatment (38.6?
Negative_regulation (initiating) of MTX in body associated with methotrexate
9) Confidence 0.21 Published 2008 Journal Yonsei Medical Journal Section Body Doc Link PMC2615375 Disease Relevance 0.96 Pain Relevance 0.38
There have been several studies suggesting that polymorphisms in some of the pathways involved in the metabolism of MTX may be useful in predicting drug outcome,19 with a recent pharmacogenetic model being used to predict drug outcome in a subset of patients.20 To date, the clinical utility of such a model has still to be fully established.
Negative_regulation (metabolism) of MTX associated with methotrexate
10) Confidence 0.19 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2596302 Disease Relevance 0.13 Pain Relevance 0.21
mL, once a day, with methotrexate (MTX) dissolved in saline 0.9% (starting dose: 0.1?
Negative_regulation (dissolved) of MTX associated with methotrexate
11) Confidence 0.19 Published 2008 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2266974 Disease Relevance 0.25 Pain Relevance 0.34
drugs equally effective; does their efficacy depend upon their being administered together with methotrexate (MTX); does efficacy depend on dose; are they more effective than MTX; are all anti-TNF?
Negative_regulation (effective) of MTX associated with methotrexate
12) Confidence 0.12 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2377247 Disease Relevance 0.97 Pain Relevance 0.59
All the studies showed significantly less progression on the vdH-S score in the MTX-IFX group The pooled results from these 4 studies including a total of 1647 patients showed a reduction in radiographic progression of 4.1 vdH-S score units (95% CI: 3.5; 4.6) per year in the MTX-IFX compared with the MTX-placebo groups (Breedveld et al 2004; St Clair et al 2004; Taylor et al 2004; Goekoop-Ruiterman et al 2005; Quinn et al 2005).
Negative_regulation (reduction) of MTX associated with infliximab
13) Confidence 0.08 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.51 Pain Relevance 0.42
Patients were randomized to switch MTX with etanercept or to add etanercept to MTX.
Negative_regulation (switch) of MTX associated with etanercept and methotrexate
14) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721350 Disease Relevance 0.16 Pain Relevance 0.85
The removal of MTX or Ara-C from the CSF is slow, which gives the rationale for the intrathecal use of these drugs.
Negative_regulation (removal) of MTX in CSF associated with methotrexate and intrathecal
15) Confidence 0.04 Published 2008 Journal International Journal of Nanomedicine Section Body Doc Link PMC2636580 Disease Relevance 0.50 Pain Relevance 0.46
Treatment with RTX + MTX dominates ETAN + MTX, ADAL + MTX and ABAT + MTX, as it is less costly and more effective.
Negative_regulation (dominates) of MTX in ADAL associated with abatacept, adalimumab and etanercept
16) Confidence 0.01 Published 2010 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2838414 Disease Relevance 0.05 Pain Relevance 0.70
Treatment with RTX + MTX dominates ETAN + MTX, ADAL + MTX and ABAT + MTX, as it is less costly and more effective.
Negative_regulation (dominates) of MTX in ADAL associated with abatacept, adalimumab and etanercept
17) Confidence 0.01 Published 2010 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2838414 Disease Relevance 0.05 Pain Relevance 0.67

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox